Dynein casts off: how an enzyme switches off the cell’s membrane motor
AI-generated hypothesis · Pre-publication · To be tested experimentally
Table of contents — full brief
- Hypothesis and mechanismCausal chain, key assumptions, residual unknowns
- State of the artVerified references and counter-evidence (DOIs)
- Falsifiable predictionsQuantitative bounds, statistical tests, H0
- Experimental protocolThree phases — in silico → minimal → full
- Impact analysisNovelty, residual gaps, available data
- Panel reviewFive personas + meta-review
Verified references
5 of 11 references- DOI: 10.1038/s41467-018-03412-8 ↗
A conserved interaction of the dynein light intermediate chain with dynein-dynactin effectors necessary for processivity
2018 - DOI: 10.1371/journal.pbio.3000100 ↗
A transient helix in the disordered region of dynein light intermediate chain links the motor to structurally diverse adaptors for cargo transport
2019 - DOI: 10.1091/mbc.E13-08-0474 ↗
Cell cycle–regulated membrane binding of NuMA contributes to efficient anaphase chromosome separation
2014 - DOI: 10.1016/s0021-9258(18)82108-1 ↗
Calmodulin binding to and cAMP-dependent phosphorylation of kinesin light chains modulate kinesin ATPase activity.
1993 - DOI: 10.1073/pnas.1916204116 ↗
Microtubule binding kinetics of membrane-bound kinesin-1 predicts high motor copy numbers on intracellular cargo
2019
+ 6 more references
Detailed panel scores
Excellent articulation between the in silico, minimal in vitro, and full-length in vivo phases, with clear GO/NO-GO/PIVOT criteria that permit a rational decision before committing substantial resources (full-length dynein, TIRF). This represents a rare example of a well-conceived sequential experimental design.
The hypothesis is mechanistically well-defined, proposing a clear and testable causal chain from specific phosphorylation events to a quantifiable change in membrane binding kinetics, grounded in established electrostatic theory (Debye-Hückel, Gouy-Chapman) and single-molecule kinetic frameworks (Kramers' rate theory).
The hypothesis proposes a clear and testable electrostatic mechanism, with precise quantitative predictions (a factor of 4–8 on Kd).
The upstream market is clear and solvent: biotechnology and pharmaceutical companies developing CDK1/cyclin B inhibitors (e.g., Pfizer, Merck KGaA, Syros Pharmaceuticals) would pay for a validated screening assay measuring the impact of drug candidates on dynein localisation, an essential mitotic cargo. The immediate need is a robust test to avoid off-target effects on vesicular transport.
A clear and testable mechanistic hypothesis is presented, with progressive validation steps (in silico, minimal, complete), thereby reducing technical risk for the funder.
Receive the next SPORE hypotheses
Once or twice a month, in your inbox. No spam, one-click unsubscribe.
Your data stays private. No third-party sharing. GDPR-compliant.